0001493152-18-009939.txt : 20180712 0001493152-18-009939.hdr.sgml : 20180712 20180712162018 ACCESSION NUMBER: 0001493152-18-009939 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20180712 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180712 DATE AS OF CHANGE: 20180712 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 18950661 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 8-K 1 form8-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): July 12, 2018

 

Rennova Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35141   68-0370244
(Commission File Number)   (I.R.S. Employer Identification No.)

 

400 S. Australian Avenue, Suite 800, West Palm Beach,
Florida
  33401
(Address of Principal Executive Offices)   (Zip Code)

 

(561) 855-1626
(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On July 12, 2018, Rennova Health, Inc. (the “Company”) issued a press release providing an update on its second quarter ended June 30, 2018. A copy of the press release is attached as Exhibit 99.1 to this report.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Exhibit Description
     
99.1   Press Release dated July 12, 2018

 

2 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 12, 2018 RENNOVA HEALTH, INC.
     
  By: /s/ Seamus Lagan
    Seamus Lagan
    Chief Executive Officer
    (principal executive officer)

 

3 
 

 

EXHIBIT INDEX

 

Exhibit No.   Exhibit Description
     
99.1   Press Release dated July 12, 2018

 

4 
 

EX-99.1 2 ex99-1.htm

 

 

Rennova Health gives update on second quarter

 

WEST PALM BEACH, Fla. (July 12, 2018) – Rennova Health, Inc. (OTCQB: RNVA), (OTCQB: RNVAW), (“Rennova” or the “Company”), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers that acquired its second rural hospital in Tennessee on June 1, 2018, announces that its second quarter revenue has shown significant growth.

 

Rennova is pleased to announce preliminary second quarter net revenues of approximately $3.42 million. This number remains subject to final review and potential adjustment. This represents an increase of approximately $1.82 million from the reported net revenues from the first quarter and includes the first month from Rennova’s second hospital which it acquired on June 1, 2018. The Company continues to take a conservative position on revenue recognition in hospital operations and will maintain this position until we have adequate historical months to evidence total collection rates.

 

The acquired hospital, Jamestown TN Medical Center, received confirmation from the Centers for Medicare and Medicaid Services on June 29, that they had processed and approved the Change of Ownership and Provider Tie-in process. Billing has now started and the Company believes it will receive its first collections in a matter of weeks.

 

“We are pleased to have our second hospital starting to add to revenues and look forward to receipt of our first payments for services provided,” said Seamus Lagan, CEO of Rennova. “We remain confident that our two hospitals will be profitable and contribute in excess of $2 million a month to sales revenue in full operation and we look forward to exploring other opportunities for expansion of revenues or acquisition in the same geographic location.”

 

Rennova is also pleased to announce that it has ordered a new 64 slice CT scanner for its Oneida based hospital. The new state of the art high resolution machine should be installed and in operation before the end of July. This addition will replace the existing aged machine and increase the services that can be offered to the communities served and to local physicians that currently send patients to other hospitals for high resolution scans. The Company expects this investment to immediately create increased revenues.

 

“We look forward to a significant improvement in the revenues and performance in Rennova in the coming quarters,” said Marlene McLennan, the recently appointed CFO of Rennova. “We expect to file our second quarter financial report to June 30 on time by August 14 and are making every effort to have it completed and filed earlier if possible”.

 

About Rennova Health, Inc.

 

Rennova provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcomes. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com.

 

   

 

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Contacts:

Rennova Health, Inc.

Sebastien Sainsbury, 561-666-9818

ssainsbury@rennovahealth.com

 

# # #

 

   

 

 

GRAPHIC 3 image_001.jpg begin 644 image_001.jpg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end